CN1603822A - Method for detecting phosphate radical in blood - Google Patents
Method for detecting phosphate radical in blood Download PDFInfo
- Publication number
- CN1603822A CN1603822A CN 200410088432 CN200410088432A CN1603822A CN 1603822 A CN1603822 A CN 1603822A CN 200410088432 CN200410088432 CN 200410088432 CN 200410088432 A CN200410088432 A CN 200410088432A CN 1603822 A CN1603822 A CN 1603822A
- Authority
- CN
- China
- Prior art keywords
- solution
- blood
- phosphate radical
- cuvette
- visible light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
This invention can qualitative and quantitative measure the phosphate radical content in blood by use of HEPES buffer solvent with PH value 6.5 to 7.5 and with pyrocatechol violet and ytterbium ion as color-developing agent. This method is free of interference of other contents and can be used in clinic.
Description
Technical field:
The present invention relates to a kind of detection method of phosphate radical, specifically belong to a kind of method that detects phosphate radical in the blood.
Background technology:
Phosphorus is one of more element of content in human body, is only second to calcium.80 percent and calcium in conjunction with and be stored in bone and the tooth, be distributed in remaining 20 percent minute in the soft tissue such as nerve fiber, the inorganic phosphate in the blood only accounts for few part, constitutes the buffer system of blood.Containing the then possible situation of too much inorganic phosphate in the blood is: hypoparathyroidism, late period chronic nephritis, vitamin D picked-up too much, Huppert's disease or be in the union phase.Inorganic phosphate is low excessively in the blood, may have hyperparathyroidism, tubular degeneration pathology, rickets or diseases such as osteomalacia, parathyroid secondary hyperplasia, long-term diarrhea or malabsorption.Therefore, clinically, measure the conventional method of the index of inorganic phosphate in the blood as blood sample analysis.
About measuring the phosphate radical of blood, method both domestic and external in the past can reduce following several:
1, the use chromatography of ions detects the phosphate radical (L.Opliti, R.Chiaraluce, V.Consalvi, N.Cetulli and R.Scandurra, Clinica Chimica Acta, 184 (1989) 155-166) in the blood;
2, sequence injection immobilized enzyme method is measured the inorganic phosphate radical (M.D.Luque de Castro, RafaelQuiles.Juan M.Fern á ndez-Romero, and Ernesto Fern á ndez, Clin.Chem, 41/1 (1995) 99-102) in the blood;
3, use phosphate radical (Suzanne L.Tobey and Eric V.Anslyn, Organic Letter, Vol.5, No.12, (2003) 2029-2031) in the synthetic receptor determination blood;
But there are some problems respectively in these above methods:
1, chromatography of ions is measured the phosphate radical in the blood clinically because the narrow range of linearity needs dilute blood, just can go to measure.
2, sequence injection immobilized enzyme method is measured the inorganic phosphate radical in the blood, is subjected to reduce the interference of hydrogen peroxide material.
3, use phosphate radical in the synthetic receptor determination blood,, also can be subjected to the water miscible restriction of acceptor simultaneously, so bring many inconvenience to surveying work owing to need a large amount of synthetic works and need the screening acceptor.
Summary of the invention:
The object of the present invention is to provide a kind of simple, sensitive, fast, the method for phosphate radical in the detection by quantitative blood.
The invention provides a kind of method that detects phosphate radical in the blood, this method phosphate radical that to be developer based on ytterbium ion, with the pyrocatechol violet detect in pH is the HEPES buffer solution of 6.5-7.5 quantitatively in the blood, it is as follows that it specifically detects step:
1, get human blood sample, the centrifugal yellowish clear liquid in upper strata that gets was placed 2 hours on high speed tabletop centrifuge;
2, get the yellowish clear liquid in above-mentioned upper strata, change the ultrafiltration cup over to, in room temperature and 5 * 10
5Use the PM-10 ultra filtration membrane ultrafilter ultrafiltration of molecular cut off under the condition of nitrogen gas of Pa, collect the colourless limpid liquid that leaches ,-17 ℃ to-20 ℃ preservations, for measurement as 10kD;
3, the HEPES buffer solution of preparation pH6.5-7.5, and prepare 2 * 10
-3The Yb of M
3+Solution and 2 * 10
-3The pyrocatechol violet solution of M;
4, the HEPES buffer solution of 2ml is added in the clean ultraviolet cuvette,, draws 2 * 10 with microsyringe as blank
-3The pyrocatechol violet solution 10-100 μ l of M is added in this cuvette, and solution is detected on the UV, visible light spectrophotometer by colourless flavescence at this moment, and 443nm has absorption maximum;
5, in above-mentioned cuvette, add 2 times of molal quantitys to the Yb of pyrocatechol violet solution
3+Solution, solution is detected on the UV, visible light spectrophotometer by xanthochromia indigo plant at this moment, finds that maximum absorption band becomes 623nm by above-mentioned 443nm;
6, get above-mentioned colourless limpid liquid, be added in this cuvette with microsyringe gradually, application of sample limit, limit is detected on the UV, visible light spectrophotometer, adding along with limpid liquid, maximum absorption band is become again to 443nm gradually by 623nm again, and the color of solution is also returned yellow by blue stain gradually, when absorption peak reaches maximum at 443nm, during the complete flavescence of the color of solution, stop to add limpid liquid;
7, by [Yb
3+] * 2/V
BloodCalculate the content of phosphate radical in the blood.
Described Yb
3+Solution is YbCl
3Solution or Yb (ClO
4)
3Solution.
Described Yb
3+Can use Nd
3+, Sm
3+, Gd
3+, Er
3+Or Ho
3+Replace.
The present invention has following advantage: 1, do not need synthetic any reagent, detect on the UV, visible light spectrophotometer, testing process is simple, and can with the naked eye obviously observe this effect; 2, our detection method has shown good selectivity to phosphate radical; 3, our detection is quantitative, the very big range of linearity is arranged, and error is very little; Obviously, this invention can be applied to the phosphate radical that detects clinically in the blood.
Description of drawings:
Fig. 1 to Fig. 8 is the UV, visible light absorption figure of phosphate radical in the detection blood of corresponding embodiment 1 to embodiment 8.
Embodiment:
Embodiment 1:
Get human blood sample, centrifugal that the yellowish clear liquid in upper strata was placed 2 hours on TGL-16B type high speed tabletop centrifuge; Get the yellowish clear liquid 6ml in above-mentioned upper strata, change 10ml ultrafiltration cup over to, in room temperature and 5 * 10
5Use the PM-10 ultra filtration membrane of molecular cut off under the condition of nitrogen gas of Pa,, collect the colourless limpid liquid that leaches ,-17 ℃ to-20 ℃ preservations, for measurement with Amicon Model 8010 ultrafilter ultrafiltration as 10kD; HEPES (10mM) buffer solution of preparation pH7.0, and prepare 2 * 10
-3The YbCl of M
3Solution and 2 * 10
-3The pyrocatechol violet solution of M; The HEPES buffer solution of 2ml is added in the clean ultraviolet cuvette,, draws 2 * 10 with microsyringe as blank
-3The pyrocatechol violet solution 50 μ l of M are added in this cuvette, and solution is detected on the UV, visible light spectrophotometer by colourless flavescence at this moment, and 443nm has absorption maximum; In above-mentioned cuvette, add 2 * 10
-3The Yb of M
3+Solution 100 μ l, solution is detected on the UV, visible light spectrophotometer by xanthochromia indigo plant at this moment, finds that maximum absorption band becomes 623nm by above-mentioned 443nm; Get above-mentioned limpid liquid, be added in this cuvette with microsyringe gradually, application of sample limit, limit is detected on HP8453 UV, visible light spectrophotometer, adding along with limpid liquid, maximum absorption band is become again to 443nm gradually by 623nm again, and the color of solution is also returned yellow by blue stain gradually, when absorption peak reaches maximum at 443nm, during the complete flavescence of the color of solution, this moment, limpid liquid addition was 90 μ l; Calculate: 100 * 2/90, in the blood phosphate content be 2.22mmol/L, UV, visible light absorption figure sees Fig. 1.
Press embodiment 1 and survey 10 human bloods, in the blood phosphate content be 1.42-2.22mmol/L with the blood of statistics medically in inorganic phosphate content range (0.81-2.26mmol/L) surely close.
Embodiment 2: HEPES (10mM) buffer solution of preparation pH6.5, all the other are with embodiment 1, in the blood phosphate content be 2.22mmol/L, UV, visible light absorption figure sees Fig. 2.
Embodiment 3: with Yb (ClO
4)
3Solution, get another people's blood, all the other are with embodiment 1,100 * 2/125, in the blood phosphate content be 1.60mmol/L, UV, visible light absorption figure sees Fig. 3.
Embodiment 4: use ErCl
3Solution, all the other all the other with embodiment 1,100 * 2/90, in the blood phosphate content be 2.22%, UV, visible light absorption figure sees Fig. 4.
Embodiment 5: use NdClO
4)
3Solution, all the other are with embodiment 1,100 * 2/90, in the blood phosphate content be 2.22mmol/L, UV, visible light absorption figure sees Fig. 5.
Embodiment 6: use SmClO
4)
3Solution, all the other are with embodiment 1,100 * 2/90, in the blood phosphate content be 2.22mmol/L, UV, visible light absorption figure sees Fig. 6.
Embodiment 7: use GdCl
3Solution, all the other are with embodiment 1,100 * 2/90, in the blood phosphate content be 2.22mmol/L, UV, visible light absorption figure sees Fig. 7.
Embodiment 8: use HoCl
3Solution, all the other are with embodiment 1,100 * 2/90, in the blood phosphate content be 2.22mmol/L, UV, visible light absorption figure sees Fig. 8.
Claims (3)
1, a kind of method that detects phosphate radical in the blood is characterized in that, this method comprises following detection step:
(1) get human blood sample, the centrifugal yellowish clear liquid in upper strata that gets was placed 2 hours on high speed tabletop centrifuge;
(2) get the yellowish clear liquid in above-mentioned upper strata, change the ultrafiltration cup over to, in room temperature and 5 * 10
5Use the PM-10 ultra filtration membrane ultrafilter ultrafiltration of molecular cut off under the condition of nitrogen gas of Pa, collect the colourless limpid liquid that leaches ,-17 ℃ to-20 ℃ preservations, for measurement as 10kD;
(3), the HEPES buffer solution of preparation pH6.5-7.5, and prepare 2 * 10
-3The Yb of M
3+Solution and 2 * 10
-3The pyrocatechol violet solution of M;
(4), the HEPES buffer solution of 2ml is added in the clean ultraviolet cuvette, as blank, with microsyringe absorption 2 * 10
-3The pyrocatechol violet solution 10-100 μ l of M is added in this cuvette, and solution is detected on the UV, visible light spectrophotometer by colourless flavescence at this moment, and 443nm has absorption maximum;
(5), in above-mentioned cuvette, add 2 times of molal quantitys to the Yb of pyrocatechol violet solution
3+Solution, solution is detected on the UV, visible light spectrophotometer by xanthochromia indigo plant at this moment, and maximum absorption band becomes 623nm by above-mentioned 443nm;
(6), get colourless limpid liquid, be added in this cuvette with microsyringe gradually, application of sample limit, limit is detected on the UV, visible light spectrophotometer, adding along with limpid liquid, maximum absorption band is become again to 443nm gradually by 623nm again, and the color of solution is also returned yellow by blue stain gradually, when absorption peak reaches maximum at 443nm, during the complete flavescence of the color of solution, stop to add colourless limpid liquid;
(7), by [Yb
3+] * 2/V
BloodCalculate the content of phosphate radical in the blood.
2, by the described a kind of method that detects phosphate radical in the blood of claim 1, it is characterized in that described Yb
3+Solution is YbCl
3Solution or Yb (ClO
4)
3Solution.
3, by claim 1 or 2 described a kind of methods that detect phosphate radical in the blood, it is characterized in that described Yb
3+Can use Nd
3+, Sm
3+, Gd
3+, Er
3+Or Ho
3+Replace.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100884329A CN1295509C (en) | 2004-11-03 | 2004-11-03 | Method for detecting phosphate radical in blood |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100884329A CN1295509C (en) | 2004-11-03 | 2004-11-03 | Method for detecting phosphate radical in blood |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1603822A true CN1603822A (en) | 2005-04-06 |
CN1295509C CN1295509C (en) | 2007-01-17 |
Family
ID=34667142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100884329A Expired - Fee Related CN1295509C (en) | 2004-11-03 | 2004-11-03 | Method for detecting phosphate radical in blood |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1295509C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102353671A (en) * | 2011-06-27 | 2012-02-15 | 董理 | Method and kit for detecting serium inorganic phosphorus |
CN103257137A (en) * | 2012-02-17 | 2013-08-21 | 谱尼测试科技股份有限公司 | Method of determining content of methyl ethyl ketone peroxide in workplace air through UV spectrophotometer |
CN104267029A (en) * | 2014-10-23 | 2015-01-07 | 攀枝花钢企欣宇化工有限公司 | Quantitative analysis method for phosphate radical |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1221111A (en) * | 1997-12-23 | 1999-06-30 | 罗瑞彪 | Research for appearing protein blotting by eosinedyeing method |
EP1215501A1 (en) * | 2000-11-30 | 2002-06-19 | Molecular Devices Corporation | Use of a poly(amino-acid)-metal ion complex to link a label to a species of interest |
-
2004
- 2004-11-03 CN CNB2004100884329A patent/CN1295509C/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102353671A (en) * | 2011-06-27 | 2012-02-15 | 董理 | Method and kit for detecting serium inorganic phosphorus |
CN103257137A (en) * | 2012-02-17 | 2013-08-21 | 谱尼测试科技股份有限公司 | Method of determining content of methyl ethyl ketone peroxide in workplace air through UV spectrophotometer |
CN104267029A (en) * | 2014-10-23 | 2015-01-07 | 攀枝花钢企欣宇化工有限公司 | Quantitative analysis method for phosphate radical |
Also Published As
Publication number | Publication date |
---|---|
CN1295509C (en) | 2007-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1149173B1 (en) | Method for determining the concentration of thrombin inhibitors | |
US8357539B2 (en) | Activated partial thromboplastin time measuring reagent, activated partial thromboplastin time measuring method, and determination method for determining presence or absence of blood coagulation inhibitor | |
Haeckel | Assay of creatinine in serum, with use of fuller's earth to remove interferents. | |
AU610412B2 (en) | Composition and method of assaying liquids for specific gravity | |
Vılchez et al. | Determination of the antibacterial norfloxacin in human urine and serum samples by solid-phase spectrofluorimetry | |
CN101776675A (en) | Novel detection method of injection use compound amoxicillin sodium and clavulanate potassium | |
EP0215170B1 (en) | Single color reading method for determining fructosamine | |
Christensen et al. | International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy | |
CN1295509C (en) | Method for detecting phosphate radical in blood | |
EP2511707B1 (en) | Method for detection of basic peptide and reagent for detection of basic peptide | |
CN101477059B (en) | Method for rapidly detecting inorganic phosphorus in water solution | |
Bergqvist et al. | Detection and determination of antimalarial drugs and their metabolites in body fluids | |
CN110714051B (en) | Protein C activity determination kit | |
Blessborn et al. | A new approach to evaluate stability of amodiaquine and its metabolite in blood and plasma | |
AU2001241744B2 (en) | Biosynthetic carbohydrate-deficient transferrin references | |
Joseph-Charles et al. | Simultaneous determination of naphazoline nitrate and tetramethylthionine base in eye drops by first-derivative UV spectrophotometry | |
CN1313818C (en) | Method for detecting phosphate radical in urine | |
Wyatt et al. | Factors affecting a cyanogen bromide-based assay of thiamin. | |
EP1256802B1 (en) | Method for examination of feces occult blood | |
US20210317505A1 (en) | Improved detection of anticoagulants in body fluids | |
US5514592A (en) | Method and composition for testing blood for hemoglobin S that incorporates mineral oil as an insoluble upper phase | |
Patel et al. | A review—qualitative and quantitative analysis of antimalarial drugs and their metabolites in body fluids | |
Coffman et al. | Stability of reserpine injections and tablets submitted by US hospitals | |
Kamble et al. | Accelerated Stability Study of Arsenazo III Used for Detection of Calcium from biological system through UV-Spectrophotometer, Biochemistry analyzer, pH meter, HPLC and HPTLC | |
Melethil et al. | Binding of gold to bovine serum albumin using flameless atomic absorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070117 Termination date: 20091203 |